Medicare AdvantageCoverageMedium impact
MA06.001g, Apheresis Therapy
Independence Blue Cross·Hematology, Oncology, Nephrology +1 more·Medical Policy
Effective date
Jun 8, 2026
We identified it
Jun 19, 2026
Summary
Policy MA06.001g regarding Apheresis Therapy has been updated with changes to coverage and/or reimbursement position and medical necessity criteria, effective June 8, 2026. The billing team must review updated medical necessity requirements and coverage guidelines to ensure proper claim submission and reimbursement for apheresis therapy procedures.
Action Required
By June 8, 2026: Billing and clinical teams must obtain and review the complete MA06.001g policy text to identify specific medical necessity criteria, coverage limitations, and any billing code changes. Update billing system rules, prior authorization workflows, and provider documentation templates accordingly to reflect new coverage position. Ensure all apheresis therapy claims submitted after the effective date comply with updated medical necessity criteria. Contact the payer at the provided policy URL or through standard channels to clarify specific billing codes and reimbursement rates affected by this change. Failure to implement required changes may result in claim denials or payment adjustments.